US FDA advisers vote against Otsuka's PTSD combination treatment
18/07/2025 20:45
July 18 (Reuters) - The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's 4578.T drug when used in combination with Viatris' VTRS.O Zoloft for the treatment of adults with PTSD. (Reporting by Siddhi Mahatole and Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar) ((siddhi.mahatole@thomsonreuters.com))
Recent news on Viatris
See all newsBrief: Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Deals of the day-Mergers and acquisitions
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal